Development of acute myocardial infarction in a young female patient with essential thrombocythemia treated with anagrelide: a case report
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이영열 | - |
dc.contributor.author | 임영효 | - |
dc.contributor.author | 김재훈 | - |
dc.contributor.author | 신진호 | - |
dc.contributor.author | 이재웅 | - |
dc.contributor.author | 김경수 | - |
dc.contributor.author | 김순길 | - |
dc.contributor.author | 김정현 | - |
dc.contributor.author | 임헌길 | - |
dc.date.accessioned | 2022-12-20T17:19:05Z | - |
dc.date.available | 2022-12-20T17:19:05Z | - |
dc.date.created | 2022-09-19 | - |
dc.date.issued | 2010-06 | - |
dc.identifier.issn | 2287-979X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/174787 | - |
dc.description.abstract | Essential thrombocythemia (ET) is a chronic myeloproliferative disorder with a prolonged clinical course. Since this disorder is considered to be at increased risk of thromboembolism, therapy is mainly focused on the decreased risk of thrombohemorrhagic events by use of cytotoxic agents. Anagrelide is a phosphodiesterase III inhibitor which is utilized in the treatment of ET for the reduction of platelets. However, patients treated with anagrelide might experience cardiovascular adverse effects including myocardial infarction (MI), although these events are rare. Herein, we report a case of a 30-year-old female with well controlled ET by anagrelide, who eventually developed an acute non-ST elevation myocardial infarction (MI). There has no found any cardiovascular risk factors in this ET patient, strongly suggesting that anagrelide might be the cause of MI. Therefore, cardiovascular function should be monitored in those patients prescribed with anagrelide. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한혈액학회 | - |
dc.title | Development of acute myocardial infarction in a young female patient with essential thrombocythemia treated with anagrelide: a case report | - |
dc.title.alternative | Development of acute myocardial infarction in a young female patient with essential thrombocythemia treated with anagrelide: a case report | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 임영효 | - |
dc.identifier.doi | 10.5045/kjh.2010.45.2.136 | - |
dc.identifier.bibliographicCitation | Blood Research, v.45, no.2, pp.136 - 138 | - |
dc.relation.isPartOf | Blood Research | - |
dc.citation.title | Blood Research | - |
dc.citation.volume | 45 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 136 | - |
dc.citation.endPage | 138 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART001452586 | - |
dc.description.journalClass | 2 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Anagrelide | - |
dc.subject.keywordAuthor | Essential thrombocythemia | - |
dc.subject.keywordAuthor | Acute myocardial infarction | - |
dc.identifier.url | http://click.ndsl.kr/servlet/OpenAPIDetailView?keyValue=01866548&target=NART&cn=NART54966221 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.